Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Chemotherapy vs Chemotherapy +/- Nivolumab in 1L HER2-negative Advanced Gastric/GEJ Adenocarcinoma
NCT07700979Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Sep 2026
- Primary completion
- Aug 2029
- Countries
- 4
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Sep 2026; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07700979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700979.